United Therapeutics CORP Form 4 insider transactions

United Therapeutics CFO James Edgemond exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised stock options and sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond executed a Rule 10b5-1 trading plan, resulting in the sale of 10,000 shares of common stock.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the sale of common stock acquired through stock option exercises, executed under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving common stock on May 26, 2026.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-arranged Rule 10b5-1 plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed a series of stock option exercises and sales totaling 9,500 shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp. reports that EVP & General Counsel Paul A. Mahon executed a pre-arranged 10b5-1 plan, involving the exercise of stock options and sale of common stock.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving common stock, including option exercises and sales under a 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Chairperson and CEO Martine Rothblatt executed a scheduled sale of 9,500 shares following an option exercise under a Rule 10b5-1 trading plan.

CFO James Edgemond exercised options and sold 10,000 shares of United Therapeutics under a pre-arranged trading plan.

President and COO Michael Benkowitz transferred 11,728 stock options to a family trust.

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a Rule 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a transaction involving the acquisition of 9,500 common shares on May 12, 2026, under a 10b5-1 trading plan.

Nilda Mesa, a Director at United Therapeutics Corp., reported the sale of 258 shares of common stock on May 12, 2026, for $581.935 per share.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a series of stock transactions on May 8, 2026, involving the exercise of stock options and subsequent sale of common stock under a 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the sale of 10,000 shares of common stock on May 7, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a series of stock transactions on May 7, 2026, involving the exercise of stock options and subsequent sale of common stock.

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock on May 7, 2026, under a 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the sale of common stock executed under a pre-arranged 10b5-1 trading plan.

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the exercise of stock options and sale of 10,000 shares of common stock on May 4, 2026, as part of a pre-arranged trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock on May 1, 2026, under a Rule 10b5-1 trading plan.